Ovarian cancer mutational processes drive site-specific immune evasion
2022 · Nature · 272 citations
https://doi.org/10.1038/s41586-022-05496-1
Y
Ying L. Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
162
Papers
2.2K
Citations
24
h-index
45
i10-index
Ying L. Liu is an academic researcher from Shangrao Normal University. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Genetic factors in colorectal cancer & Ovarian cancer diagnosis and treatment. The author has an h-index of 24, co-authored 138 publications.
ORCID: 0000-0001-5790-851XPapers by this author
worksComprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
2022 · Annals of Oncology · 51 citations
https://doi.org/10.1016/j.annonc.2022.01.006
Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy
2025 · Journal of Hematology & Oncology · 49 citations
https://doi.org/10.1186/s13045-025-01717-y
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis
2022 · Gynecologic Oncology · 30 citations
https://doi.org/10.1016/j.ygyno.2022.06.017
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
2022 · Cancer Epidemiology Biomarkers & Prevention · 29 citations
https://doi.org/10.1158/1055-9965.epi-21-1287
To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
2023 · Journal of Cancer Research and Clinical Oncology · 20 citations
https://doi.org/10.1007/s00432-023-04919-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat